I'm LongbridgeAI, I can summarize articles.PMV Pharmaceuticals signed an underwriting agreement with TD Securities for a $47 million offering of common stock and warrants, closing on Sep 02, 2026. The deal includes 22.05M shares and associated warrants at $1.21 per unit. Proceeds will fund late-stage development and commercialization prep for rezatapopt.
PMV Pharmaceuticals entered into an Underwriting Agreement with TD Securities to conduct an underwritten offering of common stock, pre-funded warrants, and accompanying common stock warrants, expected to close on Sep 02, 2026. The deal includes 22,055,000 shares, 19,900,000 pre-funded warrants, and 41,955,000 accompanying warrants at a combined price of $1.21 per share-unit, generating estimated net proceeds of approximately $47.0 million. Warrants are immediately exercisable, with common stock warrants expiring five years from issuance and featuring reset and potential mandatory exercise provisions tied to FDA NDA acceptance milestones. Proceeds will support late-stage development, regulatory submission, and commercialization preparation for rezatapopt.
Agreement details:
- Agreement type: Underwriting agreement for underwritten equity and warrant offering
- Counterparty: TD Securities
- Signed / Effective: Aug 31 2026 / same
- Duration / Termination: At will
- Reason: Fund late-stage rezatapopt development and commercialization prep
Original SEC Filing: PMV Pharmaceuticals, Inc. [ PMVP ] - 8-K - Sep. 01, 2026